AVBP - ArriVent BioPharma, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.00
DETAILS
HIGH:
$47.00
LOW:
$45.00
MEDIAN:
$46.00
CONSENSUS:
$46.00
UPSIDE:
62.00%
Institutional Holders (13F)
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-06-18 | Hohneker John | director | A-Award | 13,562 | $31.74 | $430K |
| 2026-06-18 | Nolet Chris | director | A-Award | 13,562 | $31.74 | $430K |
| 2026-06-18 | Parsey Merdad | director | A-Award | 13,562 | $31.74 | $430K |
| 2026-06-18 | Peterson Kristine | director | A-Award | 13,562 | $31.74 | $430K |
| 2026-02-02 | LaChapelle Robin | officer: Chief Operating Officer | A-Award | 130,000 | $22.67 | $2.9M |
| 2026-02-02 | Lutzker Stuart | director, officer: President of R&D | A-Award | 150,000 | $22.67 | $3.4M |
| 2026-02-02 | Kung Winston | officer: Chief Financial Officer | A-Award | 140,000 | $22.67 | $3.2M |
| 2026-02-02 | Yao Zhengbin | director, officer: President and CEO | A-Award | 550,000 | $22.67 | $12.5M |
| 2026-02-02 | Kastenmayer James Paul | officer: General Counsel | A-Award | 130,000 | $22.67 | $2.9M |
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | SELL | 555,555 | $23.37 | $13.0M |
| 2025-07-11 | LaChapelle Robin | officer: Chief Operating Officer | M-Exempt | 6,503 | $2.28 | $15K |
| 2025-07-11 | LaChapelle Robin | officer: Chief Operating Officer | M-Exempt | 2,600 | $2.28 | $6K |
| 2025-07-11 | LaChapelle Robin | officer: Chief Operating Officer | M-Exempt | 2,050 | $2.28 | $5K |
| 2025-06-18 | Parsey Merdad | director | A-Award | 15,502 | $24.89 | $386K |
| 2025-06-18 | Peterson Kristine | director | A-Award | 15,502 | $24.89 | $386K |
| 2025-06-18 | Hohneker John | director | A-Award | 15,502 | $24.89 | $386K |
| 2025-06-18 | Nolet Chris | director | A-Award | 15,502 | $24.89 | $386K |
| 2025-04-28 | Parsey Merdad | director | A-Award | 28,346 | $20.92 | $593K |
| 2025-04-28 | Parsey Merdad | director: | ? | -- | -- | -- |
| 2025-02-03 | Kung Winston | officer: Chief Financial Officer | A-Award | 120,000 | $27.56 | $3.3M |
| 2025-02-03 | Kastenmayer James Paul | officer: General Counsel | A-Award | 102,000 | $27.56 | $2.8M |
| 2025-02-03 | Yao Zhengbin | director, officer: President and CEO | A-Award | 380,000 | $27.56 | $10.5M |
| 2025-02-03 | Lutzker Stuart | director, officer: President of R&D | A-Award | 120,000 | $27.56 | $3.3M |
| 2025-02-03 | LaChapelle Robin | officer: Chief Operating Officer | A-Award | 120,000 | $27.56 | $3.3M |
| 2024-09-19 | LaChapelle Robin | officer: Chief Operating Officer | M-Exempt | 2,700 | $6.24 | $17K |